A recent meta-analysis by Guo et al., assessing the risk of hepatoxicity following different treatment regimens involving anti-PD-(L)1 and chemotherapy, showed an elevated risk of all-grade and high-grade hepatitis with use of anti-PD-(L)1 with and without chemotherapy, compared to chemotherapy alone [153]. This evidence concerns the gene CD274 and hepatitis A virus infection.